Needham Rates Definium Therapeutics (DFTX) buy, $50 Price Target

Needham continues to back Definium Therapeutics with a buy rating and a $50 price target, a 18.68% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 7:01 AM EDT · Updated Jun 25, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $50 price target on June 23, 2026.

Since the rating, $DFTX is up 30.0% after 1 week, up 18.7% after 1 month and down 11.3% to date (from the $36.18 close on Jun 23, 2026).

DFTX Definium Therapeutics, Inc.

$32.10 +135.34% year to date

Daily close · Oct 16, 2026

Key Points

On June 23, 2026, Needham reiterated a buy rating for Definium Therapeutics, Inc. at a target price of $50.00.
Needham's $50 price target implies 18.68% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
The stock traded at $42.13 on the day of the announcement, reflecting strong market interest compared to its 52-week high of $49.70.
Analyst sentiment remains positive with a consensus recommendation of strong buy from 17 analysts, suggesting confidence in the company’s clinical developments.

Get $DFTX trade alerts by text

We text you when insiders, Congress or big funds trade $DFTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures

Needham reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a target price of $50.00 on June 23, 2026. The stock was priced at $42.13 on that day, showing how market interest has grown, especially given its recent performance against a 52-week high of $49.70.

Analyst rating track record

Needham vs. the S&P 500

YTD return +16.10% hypothetical

All-time return +85.01% S&P 500 +28.25%

vs. S&P 500 +56.76% ahead of the index

Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Definium Therapeutics

Several other funds have also taken notable positions in Definium. Blackrock Inc. increased its stake by 2,752,663 shares, ending with 11,232,834 shares worth about $361.8 million. Avoro Capital Advisors LLC added 2,188,966 shares to its holdings, totaling 7,188,888 shares valued at approximately $231.5 million. Driehaus Capital Management, LLC grew its position by 933,474 shares, bringing its total to 6,845,276 shares worth around $220.5 million. Meanwhile, Jupiter Topco LLC doubled its stake, adding 2,807,822 shares to reach 5,615,645 shares valued at about $180.9 million, while Capital World Investors also boosted its holdings by 2,683,862 shares, ending with 5,367,723 shares worth $172.9 million.

Definium Therapeutics, Inc. Stock Up 8.6%

As of June 23, 2026, Definium Therapeutics is trading at $42.13, which is close to its 50-day moving average of $42.28. The stock has shown remarkable growth from its 52-week low of $9.35, indicating strong investor confidence as they progress through clinical trials.

12-month forecast

$DFTX price target

Definium Therapeutics, Inc. daily closes and this analyst's $50 target. Not advice.

Recent Earnings

Definium has not turned a profit recently, showing an EPS of -$3.43, which underscores the speculative nature of investing in clinical-stage biopharmaceuticals. Their next earnings report is expected on November 5, 2026, which will provide further insights into their financial health and clinical progress.

Insider Buying and Selling at Definium Therapeutics, Inc.

Insider activity at Definium includes notable sales on September 25, 2026. CEO Robert Barrow sold 31,550 shares at an average price of $36.57, totaling around $1.15 million. Other insiders, including Officer Mark R. Sullivan and CFO Brandi L. Roberts, also sold shares on the same date, with shares ranging from 3,097 to 14,051, reflecting a typical pattern of insiders managing their personal holdings.

Analysts Set New Price Targets

Analysts are optimistic about Definium's prospects. On October 9, 2026, JP Morgan initiated coverage with an Overweight rating and a target of $84.00, while Canaccord Genuity maintained its Buy rating, raising the target to $78.00 from $64.00 on September 15. Baird also maintained an Outperform rating with a price target of $79.00, up from $75.00, showing a consensus that favors the company’s growth trajectory.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, focusing on developing new treatments for brain health disorders. Their lead candidates are in various stages of clinical trials, targeting conditions like generalized anxiety disorder and autism spectrum disorder. This focus on innovative therapies positions them favorably in the competitive healthcare sector.

Bottom Line

Investors should watch for Definium's upcoming earnings report on November 5, 2026, to gauge its financial performance and clinical advancements. The 13F filing indicates growing institutional interest, but keep in mind that these filings reflect past positions and may not represent current holdings.